-
12.07.2017 | Vedanta announces start of phase 1a/1b, first-in-human, clinical trial of VE303, an oral microbiome therapeutic for the treatment of recurrent C. difficile infections
BUSINESS WIRE | Vedanta’s VE303, a Powered by CARB-X project, is the first known investigational drug consisting of a rationally-defined bacterial consortium in powder form to enter the clinic. VE303 granted Orphan Drug Designation by the FDA. Business Wire, December 7, 2017
-
12.06.2017 | New antibiotic action
SCIENCE | Commentary on new agents to treat gram-negative bacterial infections
-
11.30.2017 | EligoChem Ltd., a Powered by CARB-X company, teams up with UK’s AMR Centre to focus on development of antimicrobial peptides
SELECT SCIENCE | AMR Centre are taking on an early stage programme with EligoChem to combat antimicrobial resistance
-
11.22.2017 | Powered by CARB-X partner Bugworks and other companies fighting back against India’s looming drug-resistance crisis
BBC | Bugworks has high-profile support after becoming the first company outside the US or Europe funded by the $455m (£343m) CARB-X accelerator, which supports start-ups combating antimicrobial-resistance (AMR)
-
11.22.2017 | Interview with CARB-X Executive Director Kevin Outterson on how the CARB-X model is accelerating antibacterial innovation
PHARMACEUTICAL TECHNOLOGY | Resistance to antibiotics is rising but the business model for developing new antibiotic drugs is broken. Could CARB-X, the world’s largest public-private partnership devoted to antibacterial research and development, be the answer?
-
11.21.2017 | Antimicrobial resistance: An underrated biological threat
BULLETIN OF THE ATOMIC SCIENTISTS | Alexander Fleming, who discovered penicillin, predicted an age when the efficacy of antibiotics would diminish and wither away.
-
11.15.2017 | Proteus gets helping hand from CLSI to transform itself from a research consortium into a VC-backed entity
CLSI | Proteus, a research consortium based in Edinburgh, Scotland, and backed by CARB-X, got a welcome crash course from CARB-X partner California Life Science Institute on becoming a venture-capital-backed entity
-
10.30.2017 | Preclinical antibiotic pipeline gets a pick-me-up
NATURE REVIEWS DRUG DISCOVERY | CARB-X is giving the global pre-clinical antibiotic pipeline a badly needed boost with critical support and exciting projects
-
10.26.2017 | Why it is so difficult to develop new antibiotics? A look at the scientific challenges and broken economic model of R&D work
BBC | Over-reliance on and misuse of antibiotics has led to warnings of a future without effective medicines.
-
10.16.2017 | Antabio, a Powered by CARB-X company developing Pseudomonas elastase inhibitors, raises 7.3 million Euros in a first round of Series A financing
ANABIO | This financing complements the recent CARB-X grant of up to $8,9 million awarded to Antabio in July 2017 to support the company’s Elastase Inhibitor program (PEI) for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.
-
10.06.2017 | Market watch: Innovation in the preclinical antibiotic pipeline
NATURE REVIEWS DRUG DISCOVERY | Analysis of CARB-X portfolio shows strong diversity and promise but high attrition rates for innovation suggest more incentives and support are needed to maintain positive momentum toward clinical trials.
-
09.25.2017 | Report highlights progress made in global AMR fight
CIDRAP | A new report from the United Nations Foundation and the Wellcome Trust is highlighting the progress that's been made, and the work that needs to be done, in the year since world leaders made a commitment to address antimicrobial resistance (AMR).
-
09.21.2017 | Sustaining global action on antimicrobial resistance: A report on global progress published by Wellcome Trust and the United Nations Foundation
WELLCOME TRUST | Report
-
09.11.2017 | Why infections picked up in hospitals are the big threat today, how world is trying to cope
THE INDIAN EXPRESS | A Bengaluru firm has become India's first to receive the international CARB-X grant to develop antibiotics to treat hospital-acquired infections.
-
09.04.2017 | Proteus, Powered by CARB-X partner, reports breakthrough imaging technology
PROTEUS | Imaging technology allows doctors to see instruments inside the boduy during medical procedures.
-
07.25.2017 | CARB-X awards $17.6 million to fund new antibiotic development
CIDRAP | Funds for antibiotic development; Improper antibiotic prescribing.
-
07.25.2017 | CARB-X awards $17.6M in grants to support global antibiotic development projects
Genetic Engineering and Biotechnology News
-
06.07.2017 | How we can stop antibiotic resistance
BBC | The efficacy of the world’s antibiotics is quickly decaying – the drugs we’re using to treat infections are working less and less. If we continue at this rate without intervention, we may find that there is not a single antibiotic left to treat any type of bacterial infection.
-
03.30.2017 | US-UK alliance targets the world’s deadliest superbugs
US News and World Report
-
03.30.2017 | Lung probe ‘to help cut the unnecessary use of antibiotics’
BBC
-
03.30.2017 | Quest for new antibiotics gets first major funding from global partnership
A major global partnership aimed at fighting superbugs announced Thursday that it is investing up to $48 million in research projects, including potentially the first new classes of antibiotics in decades, to target the deadliest drug-resistant bacteria. Washington Post
Toggle navigation